{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-016220","form_type":"8-K","ticker":"HRMY","cik":"0001802665","company_name":"Harmony Biosciences Holdings, Inc.","filed_at":"2023-10-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.527168+00:00","generated_at":"2026-06-10T04:55:10.001570+00:00","sec_items":["8.01","9.01"],"event_type":"litigation","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Harmony Biosciences receives generic challenge notices for WAKIX from Novugen and Lupin","bullets":["Novugen Pharma and Lupin Ltd. filed ANDAs seeking FDA approval to market generic pitolisant (WAKIX) before patent expiry.","Paragraph IV notices challenge U.S. Patents 8,486,947 & 8,207,197, expiring Sept 2029 and Mar 2030 respectively.","Patent 8,354,430 (expiring Feb 2026) is not challenged in the notices.","Company states it will vigorously defend its intellectual property rights for WAKIX."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-016220","json":"https://secwatch.observer/filing/0001558370-23-016220.json","markdown":"https://secwatch.observer/filing/0001558370-23-016220.md","text":"https://secwatch.observer/filing/0001558370-23-016220.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1802665/000155837023016220/0001558370-23-016220-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1802665/000155837023016220/hrmy-20230928x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T04:55:10.001570+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}